Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial

F. Zannad, GM. De Ferrari, AE. Tuinenburg, D. Wright, J. Brugada, C. Butter, H. Klein, C. Stolen, S. Meyer, KM. Stein, A. Ramuzat, B. Schubert, D. Daum, P. Neuzil, C. Botman, MA. Castel, A. D'Onofrio, SD. Solomon, N. Wold, SB. Ruble,

. 2015 ; 36 (7) : 425-33. [pub] 20140831

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16000644

AIM: The neural cardiac therapy for heart failure (NECTAR-HF) was a randomized sham-controlled trial designed to evaluate whether a single dose of vagal nerve stimulation (VNS) would attenuate cardiac remodelling, improve cardiac function and increase exercise capacity in symptomatic heart failure patients with severe left ventricular (LV) systolic dysfunction despite guideline recommended medical therapy. METHODS: Patients were randomized in a 2 : 1 ratio to receive therapy (VNS ON) or control (VNS OFF) for a 6-month period. The primary endpoint was the change in LV end systolic diameter (LVESD) at 6 months for control vs. therapy, with secondary endpoints of other echocardiography measurements, exercise capacity, quality-of-life assessments, 24-h Holter, and circulating biomarkers. RESULTS: Of the 96 implanted patients, 87 had paired datasets for the primary endpoint. Change in LVESD from baseline to 6 months was -0.04 ± 0.25 cm in the therapy group compared with -0.08 ± 0.32 cm in the control group (P = 0.60). Additional echocardiographic parameters of LV end diastolic dimension, LV end systolic volume, left ventricular end diastolic volume, LV ejection fraction, peak V02, and N-terminal pro-hormone brain natriuretic peptide failed to show superiority compared to the control group. However, there were statistically significant improvements in quality of life for the Minnesota Living with Heart Failure Questionnaire (P = 0.049), New York Heart Association class (P = 0.032), and the SF-36 Physical Component (P = 0.016) in the therapy group. CONCLUSION: Vagal nerve stimulation as delivered in the NECTAR-HF trial failed to demonstrate a significant effect on primary and secondary endpoint measures of cardiac remodelling and functional capacity in symptomatic heart failure patients, but quality-of-life measures showed significant improvement.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16000644
003      
CZ-PrNML
005      
20191213094912.0
007      
ta
008      
160108s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/eurheartj/ehu345 $2 doi
035    __
$a (PubMed)25176942
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Zannad, Faiez $u Inserm, CIC 1433, Centre Hospitalier Universitaire, Department of Cardiology, Nancy University, Université de Lorraine, Nancy, France f.zannad@chu-nancy.fr.
245    10
$a Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial / $c F. Zannad, GM. De Ferrari, AE. Tuinenburg, D. Wright, J. Brugada, C. Butter, H. Klein, C. Stolen, S. Meyer, KM. Stein, A. Ramuzat, B. Schubert, D. Daum, P. Neuzil, C. Botman, MA. Castel, A. D'Onofrio, SD. Solomon, N. Wold, SB. Ruble,
520    9_
$a AIM: The neural cardiac therapy for heart failure (NECTAR-HF) was a randomized sham-controlled trial designed to evaluate whether a single dose of vagal nerve stimulation (VNS) would attenuate cardiac remodelling, improve cardiac function and increase exercise capacity in symptomatic heart failure patients with severe left ventricular (LV) systolic dysfunction despite guideline recommended medical therapy. METHODS: Patients were randomized in a 2 : 1 ratio to receive therapy (VNS ON) or control (VNS OFF) for a 6-month period. The primary endpoint was the change in LV end systolic diameter (LVESD) at 6 months for control vs. therapy, with secondary endpoints of other echocardiography measurements, exercise capacity, quality-of-life assessments, 24-h Holter, and circulating biomarkers. RESULTS: Of the 96 implanted patients, 87 had paired datasets for the primary endpoint. Change in LVESD from baseline to 6 months was -0.04 ± 0.25 cm in the therapy group compared with -0.08 ± 0.32 cm in the control group (P = 0.60). Additional echocardiographic parameters of LV end diastolic dimension, LV end systolic volume, left ventricular end diastolic volume, LV ejection fraction, peak V02, and N-terminal pro-hormone brain natriuretic peptide failed to show superiority compared to the control group. However, there were statistically significant improvements in quality of life for the Minnesota Living with Heart Failure Questionnaire (P = 0.049), New York Heart Association class (P = 0.032), and the SF-36 Physical Component (P = 0.016) in the therapy group. CONCLUSION: Vagal nerve stimulation as delivered in the NECTAR-HF trial failed to demonstrate a significant effect on primary and secondary endpoint measures of cardiac remodelling and functional capacity in symptomatic heart failure patients, but quality-of-life measures showed significant improvement.
650    _2
$a elektrokardiografie ambulantní $7 D015716
650    _2
$a tolerance zátěže $x fyziologie $7 D017079
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a srdeční selhání $x patofyziologie $x terapie $7 D006333
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a bezpečnost pacientů $7 D061214
650    _2
$a kvalita života $7 D011788
650    _2
$a výsledek terapie $7 D016896
650    _2
$a vagová stimulace $x škodlivé účinky $x metody $7 D055536
650    _2
$a dysfunkce levé srdeční komory $x patofyziologie $x terapie $7 D018487
650    _2
$a remodelace komor $x fyziologie $7 D020257
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a De Ferrari, Gaetano M $u Department of Cardiology and Cardiovascular Clinical Research Center, Fondazione IRCCS, Policlinico San Matteo, Pavia, Italy.
700    1_
$a Tuinenburg, Anton E $u Department of Cardiology, University Medical Center, Utrecht, The Netherlands.
700    1_
$a Wright, David $u Department of Cardiology, Liverpool Heart and Chest, Liverpool, UK.
700    1_
$a Brugada, Josep $u Thorax Institute, Hospital Clinic, Barcelona, Spain.
700    1_
$a Butter, Christian $u Heart Centre Brandenburg Hospital, Bernau, Germany.
700    1_
$a Klein, Helmut $u Division of Cardiology, Otto-von-Guericke Universität Magdeburg, Magdeburg, Germany.
700    1_
$a Stolen, Craig $u Boston Scientific Corporation, St. Paul, MN, USA.
700    1_
$a Meyer, Scott $u Boston Scientific Corporation, St. Paul, MN, USA.
700    1_
$a Stein, Kenneth M $u Boston Scientific Corporation, St. Paul, MN, USA.
700    1_
$a Ramuzat, Agnes $u Guidant Europe, Diegem, Belgium.
700    1_
$a Schubert, Bernd $u Guidant Europe, Diegem, Belgium.
700    1_
$a Daum, Doug $u Boston Scientific Corporation, St. Paul, MN, USA.
700    1_
$a Neuzil, Petr $u Department of Cardiology, Homolka Hospital, Prague, Czech Republic.
700    1_
$a Botman, Cornelis $u Department of Cardiology, Catharina Hospital, Eindhoven, The Netherlands.
700    1_
$a Castel, Maria Angeles $u Thorax Institute, Hospital Clinic, Barcelona, Spain.
700    1_
$a D'Onofrio, Antonio $u Azienda Ospedaliera dei Colli - Monaldi, Napoli, Italy.
700    1_
$a Solomon, Scott D. $7 xx0243096 $u Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
700    1_
$a Wold, Nicholas $u Boston Scientific Corporation, St. Paul, MN, USA.
700    1_
$a Ruble, Stephen B $u Boston Scientific Corporation, St. Paul, MN, USA.
773    0_
$w MED00009622 $t European heart journal $x 1522-9645 $g Roč. 36, č. 7 (2015), s. 425-33
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25176942 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160108 $b ABA008
991    __
$a 20191213095213 $b ABA008
999    __
$a ok $b bmc $g 1102925 $s 924850
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 36 $c 7 $d 425-33 $e 20140831 $i 1522-9645 $m European heart journal $n Eur Heart J $x MED00009622
LZP    __
$a Pubmed-20160108

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace